CD274 and neoplasm: In other tumors, for example, in lung cancer, the United States Food and Drug Administration and the European Medicines Association have approved pembrolizumab (an anti-PD-1) as a first-line treatment in patients with metastatic lung cancer whose tumors have a PD-L1 expression of ≥50% with no other genomic tumor aberrations [128] (Table 1).